TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company is headquartered in Malvern, Pennsylvania and currently employs 209 full-time employees. The company went IPO on 2019-11-08. The firm is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The firm's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
Follow-Up Questions
TELA Bio Inc 的 CEO 是谁?
Mr. Antony Koblish 是 TELA Bio Inc 的 Chief Executive Officer,自 2012 加入公司。
TELA 股票的价格表现如何?
TELA 的当前价格为 $1.31,在上个交易日 increased 了 2.01%。
TELA Bio Inc 的主要业务主题或行业是什么?
TELA Bio Inc 属于 Health Care 行业,该板块是 Health Care
TELA Bio Inc 的市值是多少?
TELA Bio Inc 的当前市值是 $52.1M
TELA Bio Inc 是买入、卖出还是持有?
据华尔街分析师称,共有 7 位分析师对 TELA Bio Inc 进行了分析师评级,包括 3 位强烈买入,6 位买入,2 位持有,0 位卖出,以及 3 位强烈卖出